Daval International Ltd.
DAVAL INTERNATIONAL LIMITED is a UK-based biotechnology company focused on the development and delivery of novel and distinctive treatments for serious unmet medical needs through a combination of innovation, dedication, entrepreneurship, skilled science and partnership. From its inception in 2000, the founder and management team of Daval has had a vision of bringing effective treatments that noticeably improve the quality of life of patients suffering from some of the most serious debilitating neuro-degenerative, inflammatory and autoimmune diseases to realisation and to offer a choice over and above some of the disease modifying treatments currently available.
Daval’s lead product candidate for human medication is AIMSPRO®, a pharmaceutically produced biological product that is manufactured and processed using a unique specification that is derived from a hyperimmune caprine serum (HICS) source. AIMSPRO has completed two “proof of concept” stage clinical trials; the first for the treatment of patients with Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma) and a second for Secondary Progressive Multiple Sclerosis (SPMS). AIMSPRO has also been studied in an Investigator Initiated open-label trial for patients with Amyotrophic Lateral Sclerosis (ALS – a form of motor neuron disease). Other disease indications are under active investigation.
Ceremben® is the veterinary equivalent of AIMSPRO that has been granted a Minor Use permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of endotoxaemia in horses, which enables the sale of Ceremben to Veterinary Surgeons in Australia.
Daval was accepted as a member of the UK’s Association of the British Pharmaceutical Industry (ABPI) in December 2007 and adheres to the APBI's Code of Practice.